Redeye leaves a comment following Alzinova’s announcement that the FDA has granted Fast Track Designation (FTD) for its lead candidate ALZ-101. We view this as an important regulatory milestone that not only validates the strength of the clinical and mechanistic data generated to date but also has the potential to accelerate development timelines. Moreover, we believe the designation strengthens Alzinova’s position in ongoing partnership discussions ahead of the planned phase II initiation.
LÄS MER
